AcroMeta Group Limited (SGX: 43F) announced a non-binding term sheet with Macro HRD SG Pte. Ltd. (Macro) to form a strategic partnership aimed at entering the ambient temperature cellular logistics (ATCLS) market. The agreement outlines AcroMeta's acquisition of a strategic stake in Macro-ATCLS Pte. Ltd., the commercial entity for Macro's ATCLS technology, and grants AcroMeta an option to secure an exclusive licence to deploy the platform across Southeast Asia.
The ATCLS technology is designed to eliminate reliance on conventional refrigerated and cryogenic cold chains by using proprietary ambient-temperature preservation and reactivation methods. It is supported by Gradient Equilibrium Decision Modeling (GEDM) for real-time governance and process control, enabling living cells to be transported at ambient temperatures and reactivated at the point of use. This addresses critical limitations in the logistics of cell and gene therapies, which typically require ultra-cold handling.
The potential market is substantial: the global cell-and-gene-therapy 3PL market is projected to grow from US$1.81 billion in 2025 to US$16.95 billion by 2035, a compound annual growth rate of 25.1%. Macro estimates a serviceable addressable market of US$14.5 billion by 2032 for ambient-addressable segments, spanning stem cells, CAR-T therapy, regenerative medicine, and organ transplantation.
Lawrence Toh, Executive Director of AcroMeta, highlighted the strategic rationale: "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations."
The exclusive licensing option would cover agreed territories in Southeast Asia, including rights to appoint sub-licensees. This structure is intended to give AcroMeta a first-mover advantage in the region, with potential for future territorial expansion. The Group plans to continue evaluating strategic opportunities to support long-term growth and shareholder value.
AcroMeta, listed on the Catalist board of the Singapore Exchange since 2016, currently focuses on facility management services. This move represents a diversification into the biotech logistics sector, leveraging emerging technology with significant growth potential.
Macro HRD, established in 2024, is a biotechnology company developing scalable precision-medicine solutions, but its ATCLS technology is separate from its core therapeutic focus. The partnership underscores a shared vision for advancing healthcare logistics in Asia.
As the cell and gene therapy market expands, the ability to transport biological materials without cold chains could reduce costs and broaden access to treatments in regions with limited infrastructure. AcroMeta's entry into this space positions it to capitalise on a transformative shift in biopharmaceutical logistics.
